The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis

Michal Taler*, Irit Gil-Ad, Inna Korob, Avraham Weizman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: We have previously demonstrated the immunomodulatory activity of some selective serotonin reuptake inhibitors. Objectives: In this research, we performed an in vivo/ex vivo study to evaluate the potential immunosuppressive effect of sertraline in an experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. Methods: Mice (C57/bl EAE) were treated with sertraline (5 mg/kg) or dexamethasone (1 mg/kg) 7 days after EAE induction and then 3 times weekly (for 3 weeks). Results: Sertraline modestly improved the clinical score of EAE and attenuated the disease-induced weight loss. Sertraline also significantly decreased ex-vivo splenocyte viability, proliferation and secretion of pro-inflammatory cytokines in EAE mice. Conclusions: We suggest that sertraline might be an add-on option for multiple sclerosis treatment.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalNeuroImmunoModulation
Volume18
Issue number2
DOIs
StatePublished - Dec 2010

Keywords

  • Cytokines
  • Experimental autoimmune encephalomyelitis
  • Immune system
  • Multiple sclerosis
  • Sertraline

Fingerprint

Dive into the research topics of 'The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis'. Together they form a unique fingerprint.

Cite this